Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 3:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–56 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Quadrivalent influenza vaccine, high-dose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

NCT05227001
View directory record Official record
Conditions
Influenza, Human
Interventions
PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza saRNA, PF-07836395 Influenza saRNA, PF-07836396 Influenza saRNA, PF-07867246 Influenza saRNA, Placebo, Quadrivalent influenza vaccine (QIV), PF-07871987 Influenza saRNA, PF-07914705 Influenza saRNA, PF-07915048 Influenza saRNA
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Walnut Creek, California • Greenacres City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 10, 2026, 3:19 PM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

NCT05215327
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
16 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 10, 2026, 3:19 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

NCT04544267
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 10, 2026, 3:19 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

NCT02500680
View directory record Official record
Conditions
Influenza, Human
Interventions
MER4101, Inactivated Influenza Vaccine
Biological
Lead sponsor
Nova Immunotherapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 10, 2026, 3:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

NCT05559476
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, FLU HD vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
1,029 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
46
States / cities
Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 10, 2026, 3:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

NCT05426174
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 10, 2026, 3:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

NCT06134804
View directory record Official record
Conditions
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions
ExPEC9V, Placebo, HD quadrivalent influenza vaccine
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
24
States / cities
Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 10, 2026, 3:19 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Systems Investigation of Vaccine Responses in Aging and Frailty

NCT05291676
View directory record Official record
Conditions
Influenza
Interventions
Fluzone, Fluad
Biological
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 10, 2026, 3:19 PM EDT